What side effects does Voydeya (daprodustat) commonly cause?
Voydeya (daprodustat) is used to treat anemia in people with chronic kidney disease (CKD). The most commonly reported side effects include problems that can show up with anemia treatments in CKD, such as headache and nausea. Other effects can include fatigue and changes in lab results related to kidney disease and iron balance. [1]
What serious side effects should patients watch for?
Serious risks with anemia medicines in CKD can include blood clotting or increased risk of cardiovascular events, and abnormal blood counts. Patients should seek urgent care for symptoms such as chest pain, shortness of breath, severe headache, weakness on one side of the body, or sudden swelling/pain in an arm or leg. [1]
How do side effects compare with EPO/ESA injections?
Unlike ESA injections (like epoetin alfa or darbepoetin), daprodustat is an oral medicine that changes the body’s signaling for red blood cell production. Side-effect patterns can differ because the drugs work through different pathways, but cardiovascular and clot-related concerns still matter with anemia correction therapies in CKD. [1]
Who is more likely to get side effects?
Risk can be higher in people with:
- Higher cardiovascular risk (heart disease, prior stroke)
- Poorly controlled blood pressure
- Significant CKD-related complications
- Iron deficiency or difficulty maintaining iron levels (which affects how anemia therapy works) [1]
What should I do if I get side effects while taking Voydeya?
Call the prescriber if you develop bothersome side effects (like ongoing nausea or headaches) so the team can check blood counts, blood pressure, and iron status. If you have symptoms that could indicate a clot or stroke, seek emergency care right away. [1]
Where can I find the full side-effect list for Voydeya?
The most complete and up-to-date side-effect and warning information is in the official prescribing information for Voydeya, including a detailed adverse-reactions section and boxed or major warnings if applicable. [1]
---
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/